nach oben

European Archives of Oto-Rhino-Laryngology

Erschienen in:

26.10.2018 | Head & Neck

Abnormal activation of the Akt signaling pathway in adenoid cystic carcinoma

verfasst von: Karla Flaviana Carneiro Castelo Branco, Andre Luis Ribeiro Ribeiro, Raíssa Pinheiro de Mendonça, João de Jesus Viana Pinheiro, Maria Sueli da Silva Kataoka, Maria Vanda Catão Arnaud, Sérgio de Melo Alves Junior

Erschienen in: European Archives of Oto-Rhino-Laryngology | Ausgabe 12/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Adenoid cystic carcinoma (ACC) is an intriguing lesion because it shows a slow growth in the beginning, but a late poor prognosis due to perineural invasion, metastasis and recurrence. This study aimed to investigate whether Akt signaling would be deregulated in adenoid cystic carcinoma and its consequence in the expression of associated proteins.

Methods

The expression of the Akt, p-Akt, NFκB, β-catenin, cyclin D1 and COX-2 was assessed by immunohistochemistry in 10 cases of ACC, 17 cases of pleomorphic adenoma (PA), and 7 cases of normal salivary gland (NSG).

Results

p-Akt was overexpressed in ACC when compared to NSG. NFκB, β-catenin, and COX-2 were overexpressed in ACC and PA when compared to NSG. Most proteins were slightly higher expressed in ACC than in PA, but they never reached significance. p-Akt expression positively correlated with NFκB, β-catenin, cyclin D1 and COX-2 in ACC and PA, while this correlation trended to be negative in for these proteins (except for NFκB) in NSG using Person’s correlation analysis, but without reaching significance.

Conclusions

Our results indicate an abnormal activation of Akt signaling pathway, which can be an important regulator of tumor biology in ACC. Activated Akt correlated with the expression of NFκB, β-catenin and COX-2, which can potentially influence cell survival in ACC.

El-Nagar AK, Chan JKC, Grandis JR et al (2017) WHO classification of head and neck tumours, 4th edn. IARC Press, Lyon

Safoura S, Mohamad E, Nosrat-Allah E, Fereshte E (2011) Immunohistochemical expression of progesterone receptors in pleomorphic adenoma and adenoid cystic carcinoma. J Cancer Res Ther 7:23. https://doi.org/10.4103/0973-1482.80440 CrossRefPubMed

Deangelis AF, Tsui A, Wiesenfeld D, Chandu A (2011) Outcomes of patients with adenoid cystic carcinoma of the minor salivary glands. Int J Oral Maxillofac Surg 40:710–714. https://doi.org/10.1016/j.ijom.2011.02.010 CrossRefPubMed

Brazão-Silva MT, Cardoso SV, de Faria PR et al (2013) Adenoid cystic carcinoma of the salivary gland: a clinicopathological study of 49 cases and of metallothionein expression with regard to tumour behaviour. Histopathology 63:802–809. https://doi.org/10.1111/his.12227 CrossRefPubMed

Khan a J, DiGiovanna MP, Ross D et al (2001) Adenoid cystic carcinoma: a retrospective clinical review. Int J Cancer 96:149–158. https://doi.org/10.1002/ijc.1013 CrossRefPubMed

Giancotti FG (2014) Deregulation of cell signaling in cancer. FEBS Lett 588:2558–2570. https://doi.org/10.1016/j.febslet.2014.02.005 CrossRefPubMedPubMedCentral

Ito FA, Ito K, Vargas PA et al (2005) Salivary gland tumors in a Brazilian population: a retrospective study of 496 cases. Int J Oral Maxillofac Surg 34:533–536. https://doi.org/10.1016/j.ijom.2005.02.005 CrossRefPubMed

Chummun S, McLean NR, Kelly CG et al (2001) Adenoid cystic carcinoma of the head and neck. Br J Plast Surg 54:476–480. https://doi.org/10.1054/bjps.2001.3636 CrossRefPubMed

Gupta AK, Wilke WW, Taylor EN et al (2009) Signaling pathways in adenoid cystic cancers: implications for treatment. Cancer Biol Ther 8:1947–1951. https://doi.org/10.4161/cbt.8.20.9596 CrossRefPubMedPubMedCentral

10.

Dodd RL, Slevin NJ (2006) Salivary gland adenoid cystic carcinoma: a review of chemotherapy and molecular therapies. Oral Oncol 42:759–769. https://doi.org/10.1016/j.oraloncology.2006.01.001 CrossRefPubMed

11.

Ellington CL, Goodman M, Kono SA et al (2012) Adenoid cystic carcinoma of the head and neck: incidence and survival trends based on 1973–2007 surveillance, epidemiology, and end results data. Cancer 118:4444–4451. https://doi.org/10.1002/cncr.27408 CrossRefPubMed

12.

Altomare DA, Testa JR (2005) Perturbations of the AKT signaling pathway in human cancer. Oncogene 24:7455–7464. https://doi.org/10.1038/sj.onc.1209085 CrossRefPubMed

13.

Martini M, De Santis MC, Braccini L et al (2014) PI3K/AKT signaling pathway and cancer: an updated review. Ann Med 46:372–383. https://doi.org/10.3109/07853890.2014.912836 CrossRefPubMed

14.

de Lima MDDM, Marques YMFS, de Melo Alves S et al (2009) MDM2, P53, P21WAF1and pAKT protein levels in genesis and behaviour of adenoid cystic carcinoma. Cancer Epidemiol 33:142–146. https://doi.org/10.1016/j.canep.2009.04.016 CrossRef

15.

Younes MN, Park YW, Yazici YD et al (2006) Concomitant inhibition of epidermal growth factor and vascular endothelial growth factor receptor tyrosine kinases reduces growth and metastasis of human salivary adenoid cystic carcinoma in an orthotopic nude mouse model. Mol Cancer Ther 5:2696–2705. https://doi.org/10.1158/1535-7163.MCT-05-0228 CrossRefPubMed

16.

Bellacosa A, Chan TO, Ahmed NN et al (1998) Akt activation by growth factors is a multiple-step process: the role of the PH domain. Oncogene 17:313–325. https://doi.org/10.1038/sj.onc.1201947 CrossRefPubMed

17.

Fan CD, Lum MA, Xu C et al (2013) Ubiquitin-dependent regulation of phospho-AKT dynamics by the ubiquitin E3 LIGASE, NEDD4-1, in the insulin-like growth factor-1 response. J Biol Chem 288:1674–1684. https://doi.org/10.1074/jbc.M112.416339 CrossRefPubMed

18.

Martelli AM, Tabellini G, Bressanin D et al (2012) The emerging multiple roles of nuclear Akt. Biochim Biophys Acta Mol Cell Res 1823:2168–2178. https://doi.org/10.1016/j.bbamcr.2012.08.017 CrossRef

19.

Zhou J, Du T, Li B et al (2015) Crosstalk between MAPK/ERK and PI3K/AKT signal pathways during brain ischemia/reperfusion. ASN Neuro 7(5):1759091415602463. https://doi.org/10.1177/1759091415602463 CrossRefPubMedPubMedCentral

20.

Aggarwal BB, Shishodia S (2004) Suppression of the nuclear factor-kappaB activation pathway by spice-derived phytochemicals: Reasoning for seasoning. Ann N Y Acad Sci 1030:434–441. https://doi.org/10.1196/annals.1329.054 CrossRefPubMed

21.

Joyce D, Albanese C, Steer J et al (2001) NF-κB and cell-cycle regulation: the cyclin connection. Cytokine Growth Factor Rev 12:73–90. https://doi.org/10.1016/S1359-6101(00)00018-6 CrossRefPubMed

22.

Vivanco I, Sawyers CL (2002) The phosphatidylinositol 3-kinase—AKT pathway in human cancer. Nat Rev Cancer 2:489–501. https://doi.org/10.1038/nrc839 CrossRefPubMed

23.

Ma B, Hottiger MO (2016) Crosstalk between wnt/β-catenin and NF-κB signaling pathway during inflammation. Front Immunol. https://doi.org/10.3389/fimmu.2016.00378 CrossRefPubMedPubMedCentral

24.

Testa JR, Bellacosa a (2001) AKT plays a central role in tumorigenesis. Proc Natl Acad Sci USA 98:10983–10985. https://doi.org/10.1073/pnas.211430998 CrossRefPubMed

25.

Pitt SC, Davis R, Kunnimalaiyaan M, Chen H (2009) AKT and PTEN expression in human gastrointestinal carcinoid tumors. Am J Transl Res 1:291–299PubMedPubMedCentral

26.

Hafner C, Houben R, Baeurle A et al (2012) Activation of the PI3K/AKT pathway in merkel cell carcinoma. PLoS One 7(2):e31255. https://doi.org/10.1371/journal.pone.0031255 CrossRefPubMedPubMedCentral

27.

Scrima M, de Marco C, Fabiani F et al (2012) Signaling networks associated with AKT activation in non-small cell lung cancer (NSCLC): new insights on the role of phosphatydil-inositol-3 kinase. PLoS One 7(2):e30427. https://doi.org/10.1371/journal.pone.0030427 CrossRefPubMedPubMedCentral

28.

Brembeck FH, Rosário M, Birchmeier W (2006) Balancing cell adhesion and Wnt signaling, the key role of β-catenin. Curr Opin Genet Dev 16:51–59. https://doi.org/10.1016/j.gde.2005.12.007 CrossRefPubMed

29.

Polakis P (2007) The many ways of Wnt in cancer. Curr Opin Genet Dev 17:45–51. https://doi.org/10.1016/j.gde.2006.12.007 CrossRefPubMed

30.

Chandrashekar C, Angadi PV, Krishnapillai R (2011) Β-Catenin expression in benign and malignant salivary gland tumors. Int J Surg Pathol 19:433–440. https://doi.org/10.1177/1066896909346366 CrossRefPubMed

31.

Schneider S, Thurnher D, Seemann R et al (2016) The prognostic significance of β-catenin, cyclin D1 and PIN1 in minor salivary gland carcinoma: β-catenin predicts overall survival. Eur Arch Otorhinolaryngol 273:1283–1292. https://doi.org/10.1007/s00405-015-3609-6 CrossRefPubMed

32.

Shtutman M, Zhurinsky J, Simcha I et al (1999) The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. Proc Natl Acad Sci USA 96:5522–5527. https://doi.org/10.1073/pnas.96.10.5522 CrossRefPubMed

33.

Ramos-García P, Gil-Montoya J, Scully C et al (2017) An update on the implications of cyclin D1 in oral carcinogenesis. Oral Dis 23:897–912. https://doi.org/10.1111/odi.12620 CrossRefPubMed

34.

Greenhough A, Smartt HJM, Moore AE et al (2009) The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis 30:377–386. https://doi.org/10.1093/carcin/bgp014 CrossRefPubMed

35.

Liao Y, Hung MC (2010) Physiological regulation of Akt activity and stability. Am J Transl Res 2:19–42PubMedPubMedCentral

36.

Yin Y, Shen WH (2008) PTEN: a new guardian of the genome. Oncogene 27:5443–5453. https://doi.org/10.1038/onc.2008.241 CrossRefPubMed

37.

Yasumatsu R, Kuratomi Y, Nakashima T et al (2004) Cyclin D1 expression does not effect cell proliferation in adenoid cystic carcinoma of the salivary gland. Eur Arch Otorhinolaryngol 261:526–530. https://doi.org/10.1007/s00405-003-0724-6 CrossRefPubMed

38.

Fouad YA, Aanei C (2017) Revisiting the hallmarks of cancer. Am J Cancer Res 7:1016–1036. https://doi.org/10.1016/j.jmwh.2009.11.004 CrossRefPubMedPubMedCentral

39.

Deng J, Xia W, Miller SA et al (2004) Crossregulation of NF-κB by the APC/GSK-3β/β-catenin pathway. Mol Carcinog 39:139–146. https://doi.org/10.1002/mc.10169 CrossRefPubMed

40.

Karim RZ, Tse GMK, Putti TC et al (2004) The significance of the Wnt pathway in the pathology of human cancers. Pathology 36:120–128. https://doi.org/10.1080/00313020410001671957 CrossRefPubMed

41.

Zhang G, Zhou X, Xue L et al (2005) Accumulation of cytoplasmic beta-catenin correlates with reduced expression of E-cadherin, but not with phosphorylated Akt in esophageal squamous cell carcinoma: immunohistochemical study. Pathol Int 55:310–317. https://doi.org/10.1111/j.1440-1827.2005.01840.x CrossRefPubMed

42.

Cao Y, Prescott SM (2002) Many actions of cyclooxygenase-2 in cellular dynamics and in cancer. J Cell Physiol 190:279–286. https://doi.org/10.1002/jcp.10068 CrossRefPubMed

43.

Sobolewski C, Cerella C, Dicato M et al (2010) The role of cyclooxygenase-2 in cell proliferation and cell death in human malignancies. Int J Cell Biol 2010:1–21. https://doi.org/10.1155/2010/215158 CrossRef

44.

Chun KS, Surh YJ (2004) Signal transduction pathways regulating cyclooxygenase-2 expression: potential molecular targets for chemoprevention. Biochem Pharmacol 68:1089–1100. https://doi.org/10.1016/j.bcp.2004.05.031 CrossRefPubMed

45.

Hinz B (2002) Cyclooxygenase-2–10 years later. J Pharmacol Exp Ther 300:367–375. https://doi.org/10.1124/jpet.300.2.367 CrossRefPubMed

Titel: Abnormal activation of the Akt signaling pathway in adenoid cystic carcinoma
verfasst von: Karla Flaviana Carneiro Castelo Branco
Andre Luis Ribeiro Ribeiro
Raíssa Pinheiro de Mendonça
João de Jesus Viana Pinheiro
Maria Sueli da Silva Kataoka
Maria Vanda Catão Arnaud
Sérgio de Melo Alves Junior
Publikationsdatum: 26.10.2018
Verlag: Springer Berlin Heidelberg
Erschienen in: European Archives of Oto-Rhino-Laryngology / Ausgabe 12/2018
Print ISSN: 0937-4477
Elektronische ISSN: 1434-4726
DOI: https://doi.org/10.1007/s00405-018-5182-2

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Springer Medizin

Abnormal activation of the Akt signaling pathway in adenoid cystic carcinoma